SELLAS Life Sciences Gr 주식 (NASDAQ: SLS)

에 대한 최신 뉴스 SELLAS Life Sciences Gr (NASDAQ:SLS) 주식

SELLAS Life Sciences Gr

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Group Inc

Solasto Corp

SELECT SANDS CORP ORD by Select Sands Corp.

Select Sands Corp

Solesence Inc

Solaris Resources Inc

Solaris Resources Inc Ordinary Shares

Barclays analyst Mario Lu maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Overweight and lowers the price target from $52 to $46.

News

Price Target

Analyst Ratings

MTCH

Barclays Maintains Overweight on Match Group, Lowers Price Target to $46

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09062623/22021_203_entrecampos_roundabout_compressed-900x600-1-2.png" alt="" class="wp-image-12678" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09062623/22021_203_entrecampos_roundabout_compressed-900x600-1-2.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09062623/22021_203_entrecampos_roundabout_compressed-900x600-1-2-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09062623/22021_203_entrecampos_roundabout_compressed-900x600-1-2-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
On a mission to shrink its international footprint and contain debt, the conglomerate has sold off property holdings in what was a key European base

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The building units in a Lisbon urban renewal project were sold to the Portuguese central bank for around 190 million euros</li>
<li>Last year Fosun International spent 11.1 billion yuan on maturing bond payments</li>
</ul>

By Lee Shih Ta
More than a decade ago,&nbsp;Fosun International&nbsp;(0656.HK) used Portugal as a springboard for an overseas expansion strategy. Since then, the sprawling conglomerate has reversed course and its now chipping away at the onetime European hub of its global ambitions.
After progressively shedding non-essential assets to shore up its finances, the company has now sealed a deal to offload some of its interests in a business, retail and residential complex to be built in the heart of Lisbon.
This latest in a spate of Fosun divestments,&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0506/2025050600079.pdf">announced</a>&nbsp;on Tuesday, covers rights over units in two planned buildings in Lisbon's Entrecampos project. The conglomerate said the assets have been sold to Banco de Portugal, the country's central bank, for a base sum of 192,000 million euros, equivalent to around $218,000 million or 1.58 billion yuan.
The Lisbon city center site is being redeveloped as part of an ambitious urban renewal project headed up by the property arm of Portuguese insurer Fidelidade, in which Fosun International holds a controlling stake.
The assets involved in the transaction are part of a complex of six buildings accounting for around 19% of the expected construction area of the entire Entrecampos project.
<h4 class="wp-block-heading">Reducing real estate risks</h4>
In 2018, Fidelidade obtained multiple parcels of land from Lisbon's city authorities for around 274 million euros, covering a development area of around 25 hectares. The investment to develop the site was projected at between 750 million and 800 million euros, with plans to build around 900 housing units including 279 for sale and the rest earmarked as affordable rentals.
The complex, scheduled for completion in the second half of 2027, is also due to include offices, shops, restaurants and green space.
The company said the disposal would reduce risk exposure to the real estate business and help it to manage uncertainties on several fronts. Identifying prestigious occupiers of signature buildings enhanced the credibility of the project, while a reduction in lettable office space would mitigate leasing risk, Fosun International said. Proceeds of the sale would be used to replenish general operating funds.
Portugal has long been a linchpin in the company's expansion strategy. In 2014, Fosun International secured a controlling stake in insurer Fidelidade for 1 billion euros, and later came into possession of Portuguese private healthcare group Luz Saúde for 860 million euros. It also became a majority shareholder in Banco Comercial Português (BCP) for 175 million euros, pursuing a three-pronged strategy of building an insurance, healthcare and banking portfolio as a beachhead for a push into international markets.
However, the company started to scale back its reach in 2022, selling non-core assets and reversing some international investments to reduce its debt burden.
In January 2024, Fosun International sold 5.6% of Portuguese commercial bank Millennium BCP for 235 million euros, while retaining a stake of more than 20%. In May last year, a stake of around 99.74% held by a Fosun subsidiary in Hauck Aufhäuser Lampe (HAL), a German private bank, was sold to ABN Amro Bank for around 670 million euros. In July, a ski resort in northern Japan, Hoshino Tomamu, was sold off to Japanese real estate investment company YCH16 for around 40.8 billion yen ($280 million).
<h4 class="wp-block-heading">Sweeping sell-off over three years</h4>
Last year alone, divestment deals amounting to around 17.5 billion yuan were signed at the group level, and 30 billion yuan at the consolidated level, according to Fosun International's annual&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0330/2025033000849.pdf">results</a>&nbsp;released at the end of March. The company divested around 75 billion yuan between 2022 and 2024. Meanwhile, it paid bond holders 11.1 billion yuan last year on matured debt instruments in onshore and offshore markets.
Total liabilities at the end of 2024 edged up 1% to 214.1 billion yuan from a year earlier and the ratio of total liabilities to capital rose from 50% at the end of 2023 to 52%. But cash reserves increased by 13.88 billion yuan to 106.34 billion yuan. The company vowed to bring its interest-bearing liabilities attributable to the group down to around 50 billion yuan in one to two years' time.
Fosun International's revenue fell 3.1% last year to 192.14 billion yuan, while industrial operating profit totaled 4.9 billion yuan. The company made a loss of 4.35 billion yuan, mainly due to a book-value impairment of 5.1 billion yuan arising from Alibaba's repurchase of shares in logistics network Cainiao at a low price. Excluding that deal, it would have achieved a profit of 750 million yuan. Thus, the numbers on paper do not do justice to its operating performance.&nbsp;
The company completed a buyout of the Fosun Tourism business last year, but a similar move to take control of&nbsp;<a>its partially owned subsidiary&nbsp;</a>Shanghai Henlius Biotech（2696.HK）was thwarted by minority shareholders. In an earnings call, Chairman Guo Guangchang painted the failed plan as a shareholder vote of confidence in the future of the biopharma firm within the Fosun group.
Guo said the company had exited asset-heavy projects and moved instead into innovative industries "with great promise and broad prospects for growth".&nbsp;Fosun Pharma&nbsp;(2196.HK）acquired another 3.9% of Henlius Biotech shares in mid-April, bringing its total holdings to 63.43%.
Currently, Fosun International is trading around a 52-week low of HK $4.15 per share, having fallen around 8.8% so far this year, leaving its price-to-earnings (P/E) ratio languishing at 4.33 times. With the divestment strategy continuing apace, and the debt situation improving, there could be some upside potential. &nbsp;

Equities

Eurozone

Opinion

Trading Ideas

Real Estate

Fosun International Sheds Real Estate Assets In Portugal

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) with a Buy and maintains $40 price target.

Reiteration

GHRS

HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target

Intl Cons Airlines Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ICAGY#OTC">ICAGY</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 600 percent. This is a 225 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $7.41 billion which beat the analyst consensus estimate of $6.87 billion by 7.83 percent. This is a 6.10 percent increase over sales of $6.98 billion the same period last year.

Earnings

Earnings Beats

Internationalnsolidated Airlines Group Sponsored American Depository Receipt

ICAGY

Intl Cons Airlines Group Q1 Adj. EPS $0.05 Beats $(0.01) Estimate, Sales $7.41B Beat $6.87B Estimate

Needham analyst Charles Shi maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Buy and lowers the price target from $230 to $150.

ONTO

Needham Maintains Buy on Onto Innovation, Lowers Price Target to $150

WIIM

UEIC

UEIC stock has given up its prior loss. Universal Electronics shares were trading lower following Q1 financial results.

B of A Securities analyst Jason Kupferberg maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $76 to $80.

AFRM

B of A Securities Maintains Buy on Affirm Holdings, Raises Price Target to $80

Barclays analyst Tom O'Malley maintains MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Overweight and raises the price target from $125 to $150.

MTSI

Barclays Maintains Overweight on MACOM Technology Solns, Raises Price Target to $150

HC Wainwright &amp; Co. analyst Andrew Fein maintains PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) with a Buy and lowers the price target from $16 to $14.

PEPG

HC Wainwright & Co. Maintains Buy on PepGen, Lowers Price Target to $14

<ul>
<li>GOOGL</li>
<li>TSLA</li>
<li>GLD</li>
<li>NVDA</li>
<li>BULL</li>
<li>PLTR</li>
<li>GOOG</li>
<li>MSTR</li>
<li>WOLF</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

BULL

GOOG

GOOGL

MSTR

NVDA

PLTR

TSLA

WOLF

Top 10 Trending Stocks On WallStreetBets As Of May 9, 2025 (Via Swaggy Stocks)

Nippon Telegraph (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTTYY#OTC">NTTYY</a>) reported quarterly earnings of $0.01 per share. This is a 40 percent decrease over earnings of $0.02 per share from the same period last year. The company reported $23.97 billion in sales this quarter. This is a 2.77 percent decrease over sales of $24.65 billion the same period last year.

NTTYY

Nippon Telegraph Q4 EPS $0.01 Down From $0.02 YoY, Sales $23.97B Down From $24.65B YoY

B of A Securities analyst Shaun Kelley maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and lowers the price target from $60 to $50.

DKNG

B of A Securities Maintains Buy on DraftKings, Lowers Price Target to $50

Orkla (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ORKLY#OTC">ORKLY</a>) reported quarterly earnings of $0.15 per share. This is a 7.14 percent increase over earnings of $0.14 per share from the same period last year. The company reported $1.55 billion in sales this quarter. This is a 4.79 percent decrease over sales of $1.63 billion the same period last year.

ORKLY

Orkla Q1 Adj. EPS $0.15 Up From $0.14 YoY, Sales $1.55B Down From $1.63B YoY

Barclays analyst Ross Sandler maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Equal-Weight and raises the price target from $19 to $20.

LYFT

Barclays Maintains Equal-Weight on Lyft, Raises Price Target to $20

ITUB

Itau Unibanco shares are trading higher after the company reported a Q1 adjusted EPS beat.

B of A Securities analyst Justin Post maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Buy and raises the price target from $205 to $211.

EXPE

B of A Securities Maintains Buy on Expedia Group, Raises Price Target to $211

Aurora Innovation shares are trading higher following Q1 financial results. Also, Needham raised its price target on the stock from $10 to $13 and maintained a Buy rating.

Barclays analyst Alex Scott maintains Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) with a Equal-Weight and raises the price target from $38 to $40.

Barclays Maintains Equal-Weight on Lincoln National, Raises Price Target to $40

AngloGold Ashanti shares are trading higher after the company reported better-than-expected Q1 financial results.

The White House is reportedly reviving the push for a tax increase&nbsp;on the wealthiest Americans as&nbsp;part of President Donald Trump&#8216;s forthcoming tax package.
What Happened:&nbsp;The proposal recommends allowing&nbsp;the top marginal income tax&nbsp;rate cut, enacted by Trump in 2017, to lapse for the highest-income Americans.&nbsp;This would result in a tax rate increase from 37% to 39.6% for those earning more&nbsp;than $2.5 million for single&nbsp;filers or $5 million for&nbsp;joint filers. Punchbowl News was the first to share these figures with its community. 
On Wednesday, the President made this policy request. The founder of Punchbowl News, Jake Sherman, disclosed that Trump directly asked Speaker Mike Johnson (R-La.) to back this policy. The White House is of the view that this tax increase on the wealthiest will facilitate substantial tax cuts for the middle and working class and safeguard Medicaid.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f6a8;BREAKING NEWS &#8212; PRESIDENT TRUMP privately urged Speaker MIKE JOHNSON on a phone call Wednesday to raise the top tax rate and close the carried interest loophole. The White House has toyed with hiking the top rate for the last few months. But this intervention raises the…
&mdash; Jake Sherman (@JakeSherman) <a href="https://twitter.com/JakeSherman/status/1920525154024558934?ref_src=twsrc%5Etfw">May 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This proposed tax increase marks a significant departure for House Republican leadership, which had previously rejected the idea. The House Ways and Means Committee is slated to finalize the tax portion of the bill, which the president has described as his &#8220;big, beautiful bill &#8221; on Tuesday.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/05/45279335/economist-brad-setser-sounds-alarm-on-chinas-hidden-trade-surplus-suggests-billions-in-capital-outflows-a" target="_blank" rel="noreferrer noopener">Economist Brad Setser Sounds Alarm On China&#8217;s Hidden Trade Surplus, Suggests Billions In Capital Outflows Are Being Masked</a>
Why It Matters: This proposed tax hike on the wealthiest Americans has been a <a href="https://benzinga.com/news/25/04/45107801/trumps-proposed-millionaires-tax-draws-fierce-gop-pushback-doing-so-would-be-political-death-experts">contentious issue</a> within the GOP. Earlier it was reported that President Trump&#8217;s support for a tax increase on millionaires sparked a fierce debate among Republicans and conservatives. 
Speaker Johnson had previously told Fox News, &#8220;I'm not in favor of raising the tax rates&#8230;&#8221;
The President&#8217;s inclination towards increasing the marginal tax rate for those earning more than a million dollars per year was met with outrage among traditional conservatives and business circles. However, some of Trump's congressional allies showed a willingness to consider the idea, contingent on Trump's endorsement.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45308288/bitcoin-closing-in-on-104000-ethereum-dogecoin-rally-on-trade-deal-optimism-analytics-firm-highlights-the-double-edged-sword-amid-bullish-sentiment" target="_blank" rel="noreferrer noopener">Bitcoin Closing In On $104,000, Ethereum, Dogecoin Soar On Trade Deal Optimism: Analytics Firm Says Bullish Sentiment A &#8216;Double-Edged Sword&#8217; &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fracti</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

SELLAS Life Sciences Gr

뉴스

에 대한 최신 뉴스 SELLAS Life Sciences Gr (NASDAQ:SLS) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌